As the Clinical Utilities of Liquid Biopsies track chair at the Precision Medicine World Conference (PMWC) 2024 Silicon Valley, I am excited to invite you to join us for this enlightening January 24-26 program. This track will delve into the latest clinical advancements and applications of liquid biopsy and feature presentations from leading luminaries in the field. In a recent conversation, I shared my perspective on the transformative potential of liquid biopsy in early cancer detection. While we are still facing the challenges of creating a generic cancer test, the progress made in patients already diagnosed with cancer are numerous. The ability to monitor response to treatments and detect minimal residual disease (MRD) showcases the versatility of this diagnostic approach. But first and foremost, we need to emphasize the importance of focused efforts on indications with the highest need, particularly aggressive cancer types that can benefit the most from early detection. This interview provides a glimpse into the depth of discussions we'll be having at the conference.
Login Or Register To Read Full Story